Neomangiferin

Synonyms: 新芒果苷
Neomangiferin 是一种口服有效的天然黄酮类化合物,可通过调节与游离脂肪酸摄取和脂质氧化相关基因的表达部分改善非酒精性脂肪肝 (NAFLD),通过抑制 Th17/Treg 细胞分化发挥抗结肠炎作用,通过靶向上调 bas-1 进而激活自噬 (autophagy)、IIS 和 MAPK 通路发挥抗衰老和延长寿命的作用,并通过其显著的抗炎和抑制破骨细胞生成的作用具有预防人工关节置换术后假体无菌性松动的潜力。
产品编号: MS-Q17083 纯度: 99.80% CAS No.: 64809-67-2 分子式: C25H28O16 分子量: 584.48
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
20mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Neomangiferin 是一种口服有效的天然黄酮类化合物,可通过调节与游离脂肪酸摄取和脂质氧化相关基因的表达部分改善非酒精性脂肪肝 (NAFLD),通过抑制 Th17/Treg 细胞分化发挥抗结肠炎作用,通过靶向上调 bas-1 进而激活自噬 (autophagy)、IIS 和 MAPK 通路发挥抗衰老和延长寿命的作用,并通过其显著的抗炎和抑制破骨细胞生成的作用具有预防人工关节置换术后假体无菌性松动的潜力。

生物实验数据

生物活性 Neomangiferin is an orally effective natural flavonoid compound that partially ameliorates non-alcoholic fatty liver disease (NAFLD) by modulating the expression of genes related to free fatty acid uptake and lipid oxidation, exerts anti-colitis effects by inhibiting Th17/Treg cell differentiation, exerts anti-aging and lifespan-extending effects by targeting and upregulating bas-1 to activate autophagy, IIS, and MAPK pathways, and has the potential to prevent aseptic loosening of prostheses after artificial joint replacement through its notable anti-inflammatory and osteoclastogenesis-inhibiting effects.
体外研究
(In Vitro)

Neomangiferin (5-20 μM; 5 days) 可抑制 C57BL/6J 小鼠纯化脾 CD4+ T 细胞中由 TGFβ/IL-6 诱导的 Th17 细胞分化,降低 IL-17 和 RORγt 的表达。
Neomangiferin (5-20 μM; 5 days) 可促进 C57BL/6J 小鼠纯化脾 T 细胞中由抗 CD3/抗 CD28 诱导的 Treg 细胞分化,并上调 IL-10 的表达。

体内研究
(In Vivo)

Neomangiferin (25-50 mg/kg;灌胃;每日给药;持续 13 周) 可通过减少体脂和肝脂堆积、使血清及肝脏脂质与抗氧化指标恢复正常、改善葡萄糖耐量与代谢速率,以及调控肝脏中与脂肪酸摄取和氧化相关的基因及蛋白表达,显著改善雄性 SD 大鼠中由高脂饮食诱导的非酒精性脂肪性肝病 (NAFLD)。
Neomangiferin (10-20 mg/kg;口服;每日一次;连续 3 天) 可通过抑制促炎细胞因子产生并恢复 Th17/Treg 平衡,改善 TNBS 诱导的雄性 C57BL/6J 小鼠结肠炎;其中 20 mg/kg 剂量对髓过氧化物酶活性的抑制率达 73.9%,对 IL-17 水平的降低率达 63.6%。
Neomangiferin (20 mg/kg;口服;每日;连续 3 周) 可通过减少促炎细胞因子的产生、将髓过氧化物酶活性抑制 52.6%,以及恢复 Th17/Treg 平衡,改善雄性 C57BL/6 IL-10 基因敲除小鼠的自发性慢性结肠炎。
Neomangiferin (2.5-5 mg/kg,腹腔注射,隔日 1 次,共 21 天) 可呈剂量依赖性地抑制 UHMWPE 颗粒诱导的小鼠颅盖骨炎性骨溶解。

Animal Model: Sprague-Dawley (SD) (male, 7-week-old, 200 g, high-fat diet-induced NAFLD)
Dosage: 50 mg/kg BW; 25 mg/kg BW
Administration: oral gavage; daily; 13 weeks
Result: Significantly decreased body weight compared to HF control group after 3 weeks of treatment; by week 8, reduced body weight to normal control levels with high-dose treatment.
Significantly lowered relative weights of organs (liver, spleen, testicle, brain, heart) and adipose tissues (abdominal, perirenal, subcutaneous, epididymal fat) with high-dose treatment compared to HF control group.
Reduced serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST/ALT ratio, glucose (GLU), and D-3-hydroxybutyric acid (D-3H) levels, and increased serum high-density lipoprotein cholesterol (HDL-C) levels and HDL-C/TC ratio after 13 weeks of treatment compared to HF control group.
Decreased hepatic TG, TC, and malondialdehyde (MDA) levels, and increased hepatic superoxide dismutase (SOD) and glutathione peroxidase (GSH-PX) levels compared to HF control group.
Increased fecal TG and TC levels compared to HF control group.
Reduced liver fat content from 43.6% (HF control) to a statistically significant lower level, decreased body fat content, and restored brown adipose tissue size with high-dose treatment compared to HF control group.
Significantly reduced hepatic fatty droplets, lipid accumulation, and renal lipid droplet accumulation compared to HF control group.
Lowered blood glucose levels at 30, 60, 90, and 120 minutes post-glucose gavage, and reduced glucose area under the curve (AUC) compared to HF control group.
Increased respiratory exchange rate (RER), oxygen consumption (VO2), and carbon dioxide production (VCO2) with high-dose treatment compared to HF control group, correcting diurnal metabolic rhythm defect.
Upregulated hepatic mRNA and protein expression of peroxisome proliferator-activated receptor α (PPARα) and carnitine palmitoyltransferase 1a (CPT1a), and downregulated hepatic mRNA and protein expression of fatty acid transport protein 2 (FATP2) and long-chain-fatty-acid-CoA ligase 1 (ACSL1) after 13 weeks of treatment compared to HF control group.
Animal Model: C57BL/6J (male, 6 weeks old, 20-23 g, TNBS-induced colitis)
Dosage: 10 mg/kg; 20 mg/kg
Administration: p.o.; daily; 3 days
Result: Inhibited TNBS-induced colon shortening.
Reduced macroscopic colitis scores.
Suppressed myeloperoxidase activity by 73.9% (20 mg/kg dose).
Prevented TNBS-induced reduction in tight junction proteins ZO-1, occludin, and claudin-1.
Inhibited TNBS-induced ERK phosphorylation, NF-κB activation, and expression of inducible nitric oxide synthase and cyclooxygenase-2.
Reduced colon tissue levels of TNF-α by 45.5%, IL-1β by 78.1%, IL-17 by 63.6%, and IL-6 by 85.5%, while increasing IL-10 expression (20 mg/kg dose).
Inhibited TNBS-induced Th17 cell differentiation in colonic lamina propria and increased Treg cell differentiation.
Attenuated TNBS-mediated upregulation of IL-17, IFN-γ, RORγt, and T-bet mRNA, and restored TNBS-suppressed IL-10, IL-5, Foxp3, and GATA3 mRNA expression.
Animal Model: C57BL/6 IL-10 knockout (male, 13 weeks old at treatment initiation, 18-21 g, spontaneous chronic colitis)
Dosage: 20 mg/kg
Administration: p.o.; daily; 3 weeks
Result: Reduced colonic myeloperoxidase activity by 52.6%.
Improved histopathological severity of colitis.
Increased expression of tight junction proteins ZO-1, occludin, and claudin-1.
Inhibited infiltration of antigen-presenting cells.
Suppressed ERK phosphorylation, NF-κB activation, and expression of inducible nitric oxide synthase and cyclooxygenase-2.
Reduced colon tissue levels of TNF-α by 17.3%, IL-1β by 54.5%, IFN-γ by 27.8%, and IL-17 by 52.8%.
Inhibited Th17 cell differentiation in colonic lamina propria and increased Treg cell differentiation.
Suppressed IL-17 and RORγt mRNA expression.
Animal Model: C57BL/6 (8-week-old male, specific pathogen free grade, UHMWPE particles implanted into calvarial subperiosteal space)
Dosage: 2.5 mg/kg; 5 mg/kg
Administration: i.p.; every other day; 21 days
Result: Significantly increased bone mineral density (BMD) and bone volume/tissue volume ratio (BV/TV), and decreased the number of bone resorption pits and total skull porosity compared to the vehicle group, with 5 mg/kg group showing greater improvement than 2.5 mg/kg group.
Significantly reduced the number of TRAP-positive osteoclasts and the area of calvarial bone erosion compared to the vehicle group, with 5 mg/kg group showing greater reduction than 2.5 mg/kg group.
Significantly reduced serum levels of TNF-α, IL-1β, RANKL, OSCAR, and CTX-1, and increased serum OPG levels compared to the vehicle group, with 5 mg/kg group showing greater reductions in proinflammatory cytokines and osteoclast markers, and greater increase in OPG, than 2.5 mg/kg group.
性状 固体
颜色 White to light yellow

化学信息

分子量 584.48
分子式 C25H28O16
CAS No. 64809-67-2
别名 新芒果苷

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.42 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (171.09 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.7109 mL8.5546 mL17.1092 mL42.7731 mL
5 mM0.3422 mL1.7109 mL3.4218 mL8.5546 mL
10 mM0.1711 mL0.8555 mL1.7109 mL4.2773 mL
15 mM0.1141 mL0.5703 mL1.1406 mL2.8515 mL
20 mM0.0855 mL0.4277 mL0.8555 mL2.1387 mL
25 mM0.0684 mL0.3422 mL0.6844 mL1.7109 mL
30 mM0.0570 mL0.2852 mL0.5703 mL1.4258 mL
40 mM0.0428 mL0.2139 mL0.4277 mL1.0693 mL
50 mM0.0342 mL0.1711 mL0.3422 mL0.8555 mL
60 mM0.0285 mL0.1426 mL0.2852 mL0.7129 mL
80 mM0.0214 mL0.1069 mL0.2139 mL0.5347 mL
100 mM0.0171 mL0.0855 mL0.1711 mL0.4277 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础